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Abstract 
INTRODUCTION: In 2015 lower respiratory infections (LRI) were the fifth leading cause of 
death and the leading cause of death for children under five years old. Despite increasing 
advances in viral detection technology, etiology is never established for a large portion of viral 
respiratory infections. The most recent of such advancements- next-generation sequencing 
(NGS)- has greatly improved the ability to discover and/or identify rare or novel viruses. 
However, NGS platforms are still not feasible in a clinical laboratory due to cost, complexity, 
personnel, etc. The ability to screen for unknown viruses using technology that is already present 
in most clinical laboratories would offer an efficient, cost-effective way to determine which 
samples may benefit from further testing with NGS.   
OBJECTIVES: Establish a methodology for general screening of clinical respiratory samples 
for unknown or unidentified viruses. 
METHODS: Clinical nasopharyngeal swabs collected in January 2017 were examined based on 
the results of the hospital’s virus PCR panel; samples testing negative for all viruses on the panel 
were screened for the inflammatory host biomarker for viral infection CXCL10 using an ELISA. 
CXCL10-positive samples were tested for viruses not included on the panel to ensure the 
presence of a “true unknown” virus. Potential NGS approaches were concurrently investigated 
using rhinovirus-positive samples from the same population.  
RESULTS: Out of 251 patients with negative viral results from the clinical laboratory, 60 were 
found to express a high level of CXCL10 in their sample, indicating a likely viral infection. 
Twenty-eight of these were found to contain coronaviruses, and the remaining 32 were declared 
“unknown.” These unknown samples will undergo further testing through a variety of techniques 
to determine the identity of any virus present in the sample.  
  
CONCLUSION: Protein host biomarker CXCL10 is produced in human respiratory epithelial 
cells in the presence of viral infection. Screening of respiratory samples for CXCL10 provides a 
pan-viral test that does not require knowledge of a specific pathogen; this study demonstrated a 
feasible workflow that could be used to screen large numbers of clinical respiratory samples for 
the presence of unknown viruses using technology that is already widely used in clinical 
laboratories. This screening assay could serve as a low-cost way to identify samples containing 
viral pathogens that otherwise would not be detected; such samples could then be sequenced to 







The sequencing portion of this project was made possible by a collaboration between the 
Foxman Lab and Scott Handley’s laboratory at Washington University, which has developed a 
bioinformatic pipeline for viral discovery. 
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Burden of respiratory disease 
Respiratory infections are a leading cause of morbidity, mortality, and disability, and present a 
substantial economic burden in the form of hospitalizations and health care costs.1,2 Lower 
respiratory tract infections (LRIs) make up the majority of serious clinical cases, and are 
responsible for up to 4 million annual deaths globally.2 LRIs are the cause of more global deaths 
than HIV, TB, and malaria combined, and disproportionally affect children under the age of 5.1,2 
Upper respiratory infections (URIs), while not generally as clinically severe, still account for 
millions of outpatient visits and over 20 million lost days of work or school.3 In addition, patients 
with URIs may develop complications, particularly in the presence of respiratory comorbidities 
like asthma or COPD.1 
 
While LRIs like pneumonia may be caused by bacteria, only about 10-15% of URIs are 
attributed to bacterial infections, with the majority attributed to viral infections.4  Viruses pose a 
unique challenge in detection and diagnostics, and very often the etiologies of LRIs are never 
conclusively established (Graf et.al estimated that only 20-60% of cases of community-acquired 
pneumonia (CAP) have a detectable pathogen).5 There are several reasons for this: viral genomes 
(particularly in RNA viruses) are highly prone to mutations, single nucleotide polymorphisms 
(SNPs), and other forms of genetic diversity, which can lead to difficulty in identification.6,7,8 In 
addition, unlike bacteria or fungi there is no common genetic feature that all viruses share, 
making the creation of a pan-viral assay much more challenging.9,10 Thus, the inherent issue with 
clinical virology assays is that one must know which specific pathogen is being looked for when 
testing. With so many respiratory infections lacking a detectable pathogen even after exhaustive 
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testing, it follows that there must be yet-unidentified viruses circulating in humans and causing 
clinical disease. 
Virus detection and discovery methods 
Culture 
Researchers and clinicians have developed different methods for virus discovery and 
identification over the years, the most traditional being viral culture. In viral culture, a sample 
from a patient or other source is inoculated into a variety of established cell lines, and any 
observable cytopathic effects are evaluated.6,9,11 There are many benefits to cell cultures, and 
they are often used in conjunction with newer, more complex assays.12 Cultured cells and 
supernatants are a source of isolated, concentrated virus that can then be used for electron 
microscopy, serology assays, and sequencing methods.6,9,13 Culturing is the best way to isolate 
and amplify a virus, and can be done without knowing what kind of virus may be present.9,13  
 
The limits of cell cultures lie in the specific cell lines that are inoculated. Different pathogens 
thrive in different environmental conditions and often have specific requirements in order to 
survive and replicate.12 Many viruses may not grow on traditionally-used cell lines, or may not 
show any visible cytopathic effects. 6,12,14 Therefore, a negative culture does not necessarily 
indicate that the original sample contains no virus. This can sometimes be solved by culturing 
cells specific to the original environment, like human airway epithelial cells (HAE) for the 
growth of respiratory viruses.14 Another potential issue in viral cell culture is the possibility of 
mutations after several passes; selective pressure can result for specific strains or types of virus 
that are most equipped for the cell lines being used (although this issue is arguably more relevant 
for downstream research such as pathogenicity determination and assay development).6,7,12  
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Polymerase Chain Reaction 
The polymerase chain reaction (PCR) is one of the most common viral detection methods used in 
clinical laboratories. Briefly, samples are combined with small genetic segments (primers) 
complementary to the gene or area of interest that a specific pathogen is known to contain. This 
allows for the exponential replication of the target sequence, the concentration of which can be 
measured and quantified to determine the relative amount of that sequence – and therefore that 
pathogen – in a sample. PCR (or reverse-transcription PCR for RNA viruses) assays in clinical 
settings are generally sensitive enough to detect very low levels of pathogen. 
 
The downside of PCR, when it comes to virus discovery, is that the sequence of the pathogen 
must be known in order to create pathogen-specific primers and probes. Primers may be made 
that recognize a target common to a virus family or species, but even then the investigator must 
have an idea of what kind of virus may be present in the sample.15 Many clinical laboratories 
have multiplexed PCR panels that allow for the testing of many viruses in one assay. This lowers 
the workload of testing, but still only tests for specific viruses, and may miss viruses not on the 
panel or even particularly divergent strains of panel viruses.16,17 
 
Although perhaps not sufficient on its own, PCR technology is still an integral part of newer 
sequencing methods for viral discovery: it is used to identify certain genomic fragments, amplify 




Next Generation Sequencing 
Sequencing all or part of an organism’s genome and comparing it to reference sequences has 
become a promising technology in virus discovery and characterization. Metagenomics using 
next generation sequencing (NGS) technologies allows for the detection and identification of all 
genetic information present in a sample; the process has been used to characterize the viral 
population of environmental samples such as ocean water or waste.6,11,18 NGS can be used to 
amplify and sequence an unknown viral genome, which can then be compared to reference 
sequences using bioinformatic software.10,19  
 
The benefit of NGS is that it is sequence-independent; that is, it does not require a priori 
knowledge of the identity or sequence of any viruses in the sample.5,15 Samples go through an 
enrichment (of viral particles) and/or depletion (of host DNA) process and are fragmented and 
amplified using PCR or similar technology. Those fragments are then sequenced in parallel, 
creating millions of “reads” of short DNA sequences that are segments of the entire sequence of 
the original sample. These reads are then analyzed and aligned to known reference sequences.  
 
There are inherent challenges present when using NGS for viral discovery. First, in clinical 
samples the amount of viral nucleic acid is usually much lower than host DNA and RNA.11,18,19 
This means that, without certain preparation steps, any viral reads will be vastly outnumbered 
and therefore more difficult to detect and identify.7,10 For this reason, samples are usually put 
through either a viral enrichment process or a background nucleic acid depletion procedure.19,20 
Enrichment methods include ultracentrifugation and filtration to concentrate viral particles and 
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remove non-viral nucleic acid.11 Depletion is generally done with a DNAse step during the 
sample preparation process.9,11,12 
 
Sequencing is only as useful as its reference library. Reads are identified by comparing them to 
known sequences in vast reference libraries.20,21 This poses a problem when dealing with a truly 
novel virus or particularly divergent strains of known viruses; a matching sequence may not be 
found or identified as such in the available databases, making conclusions about the identity of 
sequences virus difficult.9,20 Genomic material for which no match is found (and has been 
confirmed as non-human, non-fungal, and non-bacterial) is sometimes referred to as viral “dark 
matter,” and it makes up a significant amount of reads in many viral metagenomics studies.9,20,21 
Most viruses that have been discovered to date using NGS had enough homology to known 
viruses to allow for the preliminary information on the family or species, which can then inform 
further identification processes.4,12,17 
 
While still largely confined to research laboratories, there are many clinical reasons to develop 
methods to identify a virus using NGS. During an ongoing epidemic, identifying the causative 
agent early allows for the quick development of faster PCR tests to identify cases and inform the 
beginning of vaccine or antiviral work.6,22 Deep sequencing also has the potential to identify 
distinct subtypes or SNPs that confer different resistance profiles or enhanced virulence.5,10 
Sequencing has enabled or aided in the discovery of many clinically significant viruses, 
including human metapneumovirus (hMPV), human bocavirus (HBoV), distinct subtypes of 
coronavirus, and others.4,23,24 
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Screening before NGS 
Next generation sequencing is a complex process that comes with often prohibitive costs and the 
need for advanced computing power and training. For this reason, it is largely used for research – 
either in metagenomics or clinical case studies – rather than as a diagnostic tool. At this point in 
the technology, it would be impractical to implement NGS as a general diagnostic test to be used 
in the same context as PCR panels or immunoassays.  
 
CXCL10 
CXCL10 is a pro-inflammatory chemokine produced by many different kinds of cells in the body 
in response to infection or cell damage.4,23,24 It serves as a chemoattractant, recruiting CD4+ T-
cells, monocytes, and NK cells and inducing further cytokine secretion.25,26 Its role in 
inflammation has been studied in many different contexts: it has been examined as a marker of 
increased risk of allogenic graft rejection, hepatitis-induced liver fibrosis, pre-term labor, and 
HIV progression.26–28 Previous work from the Foxman Lab showed that CXCL10 may be useful 
as a host-derived biomarker for viral diagnostics, as it is highly expressed in respiratory 
epithelial cells in the presence of an active viral infection.16 That study used nasopharyngeal 
swabs and showed that CXCL10 mRNA and protein levels were a good predictor of the presence 
of one or more viruses.16 Importantly, that study also showed that bacterial infections did not 
result in the same activation of CXCL10, confirming that this marker may be effective in 





CXCL10 as a screening method 
The goal of this project was to begin to bridge the gap between the clinical laboratory and the 
power of next generation sequencing, by developing a method to screen clinical samples to 
identify those containing truly 
unknown viruses and evaluate 
potential workflows to identify those 
viruses using NGS. We sought to 
develop a methodology to utilize 
CXCL10 as a way to screen patient 
samples for unknown or unidentifiable 
respiratory viruses. To this end we 
examined clinical respiratory samples 
(nasopharyngeal swabs) that had tested negative for all viruses on the clinical virus PCR panel to 
attempt to determine if any contained a virus that is not included in that panel, and so went 




1,109 samples of frozen viral transport media from nasopharyngeal swabs were supplied by the 
clinical laboratory at Yale New Haven Hospital (YNHH). Samples were collected in January 
2017, and transport media was kept at -80°C. Additionally, individual test information was 
provided by the clinical laboratory to break down all viral respiratory tests that had been run on 
Table 1: Respiratory Viruses in Yale New Haven 
Hospital semi-quantitative PCR Panel 
Adenovirus 
Human Metapneumovirus (hMPV) 
Rhinovirus (RV) 
Influenza A and B  
Respiratory Syncytial Virus (RSV) 
Parainfluenza 1-3, 4*(PIV 1-4) 
Coronavirus* 
*added to panel after beginning of study 
Table 1: Viruses included in YNHH respiratory panel 
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the provided nasopharyngeal 
swabs. Samples had been 
tested using a clinical PCR 
panel consisting of Influenza A 
and B, adenovirus, respiratory 
syncytial virus (RSV), 
rhinovirus (RV), Parainfluenza 
viruses 1-3 (PIV), and human 
metapneumovirus (hMPV). 
 
Out of the 1,109 samples, 732 
had been tested with a 
complete clinical PCR panel 
(see Table 1 for a list of 
included viruses). Of those, 
588 were negative (80.3%). Samples 
were organized by week; week 4, from January 22 to January 31, contained the most samples 
(n=266), so these samples were chosen for further analysis (see Figure 1a and 1b for a weekly 
breakdown of URI cases at YNHH). Some samples in the provided record did not have a 
corresponding sample or were mislabeled, bringing the final number of analyzed samples to 251. 
Data was collected on these samples including patient demographics, information on the 
encounter in which the sample was taken, and comorbidities. Samples were deidentified and 
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Figure 1: URI cases at YNHH in 2017, by week (a); Positive tests 
per virus, week 4 (b) 
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were pulled from ICD-9 codes and chart notes from the encounters for which the specific 
samples were collected.  
 
Additionally, information was collected from 33 samples from the original 1,109 that were 
positive for rhinovirus (RV) according to the clinical virus panel. These samples were used in 
initial optimization and quality control testing. 
 
The workflow for these samples is shown in Figure 2. First, samples were tested for the presence 
of CXCL10 by ELISA. Those that tested positive for CXCL10 were screened for coronavirus 
and parainfluenzavirus-4 with qPCR (these are common respiratory viruses that were not 
included in the hospital’s panel), and those that were negative were considered true unknowns 
and were carried on for further investigation  
 
Method Development and Sample Preparation 
Experiments using rhinovirus (RV)-positive samples were done to determine the optimal lysis 
buffer and storage conditions that would result in the highest RNA yield. Thawed samples were 
prepared using the following methods: thawed samples with added Qiagen AVL buffer and BME 
(Sigma) that were tested without being refrozen (referred to as “fresh”), and samples that went 
through one freeze-thaw after preparation and before testing. Freeze-thaw samples were 




CXCL10 ELISA CoV / PIV-4qPCR
251 total
samples
Figure 2: Workflow for PCR-negative samples 
 11 
RNALater RNA stabilization reagent (Qiagen). qPCR was then performed using primers for 
HPRT, b-actin, CXCL10, and rhinovirus/enterovirus (Invitrogen). Relative amounts were 
calculated based on b-actin, and are shown for both high 
and low levels of rhinovirus in Figure 3 (based on CTs 
from clinical laboratory results). Based on these results, it 
was decided that going forward, samples would be 
prepared with AVL and BME, as it would not be possible 
to use fresh samples  
 
In the final workflow used for this project, the following 
aliquots were made from each sample: the original sample 
(viral transport media) was thawed on ice, and two tubes 
of 140 µl were made for RNA isolation, to which 560 µl 
of AVL Lysis buffer (Qiagen) was added. 400 µl of 
original sample was spun down to remove cell debris; 70 µl of supernatant was added to a flat-
bottom 96-well plate for immunoassay. The remaining supernatant was transferred into a new 
tube to be used as extra material if needed. All aliquots, if not immediately used, were frozen at -
80° C.  
 
RNA extraction 
Viral RNA extraction was carried out on samples using the Qiagen QIAmp Viral RNA Mini kit 
with no added carrier RNA. Samples had been frozen with AVL lysis buffer as described above, 

















































































Figure 3: Relative amounts of 
rhino/enterovirus present in rhinovirus-
positive samples under different storage 
conditions 
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proceeding with the protocol. Extraction was done per kit instructions, with the addition of a 15-
minute DNAse (Qiagen) incubation step before elution. Samples were eluted in two elutions of 
30 µl, the first of which was used to make cDNA. Remaining eluates were stored at -80°C.  
 
cDNA was prepared from extracted RNA using the Bio-Rad iScript cDNA synthesis kit, with 4 
µl of Reaction Mix and 1 µl reverse transcriptase added to 10 µl water and 5 µl sample. This was 
run on a Bio-Rad T100 Thermal Cycler under manufacturer-recommended conditions. cDNA 
was stored at -80° when not in use.  
 
CXCL10 ELISA 
Samples were screened for CXCL10 using the R&D Systems Human CXCL10/IP-10 DuoSet 
ELISA per manufacturer’s instruction. For each 96-well plate, the assay was performed over the 
course of three days. Detection was performed on the final day, and the plates were read using a 
VersaMax Microplate Reader (Molecular Devices) at 450 nm.  
 
Standard curves were generated using the manufacturer-provided concentrations of the 
standards, and used to calculated CXCL10 concentrations (in pg/ml). The lower limit of the 
linear range was 32.25 pg/ml. Samples were run in 1:5 dilutions, making the lower limit of 
detection 61.25 pg/ml for original samples.  
 
qPCR  
Because the clinical PCR panel did not include coronavirus or parainfluenza-4 virus at the time 
that these samples were analyzed, SYBR green qPCR (Bio-Rad) was performed on CXCL10-
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positive samples with CoV and PIV-4 primers.29 Samples that were positive for CXCL10 and 
negative for CoV/PIV-4 were considered “true unknowns” to be further investigated. Some 
CXCL10 samples were also tested for ß-actin to ensure sample integrity. 
 
Initial Sequence Investigation 
The next step in a process for identifying unknown viruses may be NGS. To begin to explore the 
best options for this step, eight samples were selected. These included four clinical samples that 
were known to be RV-positive (one of which was coinfected with RSV), two RV-infected cell 
culture samples (positive controls), and two RV-negative cell culture samples (negative 
controls). RNA isolated from these samples using the above protocol was sent to the Yale Center 
for Genomic Analysis (YCGA). YCGA performed a low-input library generation protocol (using 
the Kapa Biosystems ribo-depletion kit) and sequenced samples using Illumina technology. The 
resulting data was sent to both an academic collaborator and a commercial pathogen 
identification company for analysis.  
 
RNA isolation and sequencing was chosen over DNA or total nucleic acid based on the high 
percentage of RNA respiratory viruses, while recognizing that sequencing RNA may also 
recognize DNA viruses that are actively being transcribed. Ribo-depletion was performed to 
eliminate host nucleic acids and increase sensitivity to any viral particles. 
 
Results 
Results of the procedures are summarized in Figure 4. Out of 251 patient samples, 60 (23.9%) 
were found to be CXCL10-positive by immunoassay. Of those 60, 28 (11.2% of original 251 
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samples) were found to be positive for CoV, 
using primers that included three different 
strains (229E, NL63, OC43). The remaining 32 
(12.7%) CXCL10-positive samples tested 
negative for CoV and PIV-4 via qPCR, and 
were considered true unknowns. 
 
The 251 samples that made up our study 
population are described in Table 2. The 
average age of the patients associated with the 
samples was 59.9. 43.0% were over the age of 
65, with 79.2% being over the age of 45. Females accounted for 61.0% of the samples, and the 
majority were from Caucasian patients (57%). Most samples came from inpatients (80.5%), 
many of whom were admitted from the emergency department. 53.4% of patients presented with 
respiratory symptoms and 19.5% were febrile. 10.4% reported cardiac related symptoms, such as 
chest pain or pressure, tachycardia, etc. It’s important to note that these symptoms are also 
commonly seen in respiratory infections and should not be considered solely indicative of a 













(deep squence, cell culture, etc) 
Figure 4: Summary of results 
 15 
Table 2. Description of samples (n=251) 
 N (%)* 
Age  
    <5 9 (3.6) 
    6-15 2 (0.8) 
    16-25 13 (5.2) 
    26-45 28 (11.2) 
    46-55 35 (13.9) 
    56-65 56 (22.3) 
    >65 108 (43.0) 
Gender  
    Male 98 (39.0) 
    Female 153 (61.0) 
Race/Ethnicity  
    White 143 (57.0) 
    Black 67 (26.7) 
    Hispanic 32 (12.8) 
    Other/Unknown 9 (3.6) 
Patient Status  
    Inpatient 202 (80.5) 
    Outpatient 23 (9.2) 
    ED 21 (8.4) 
    Unknown 5 (2.0) 
Presenting symptoms  
    Respiratory 134 (53.4) 
    Fever 49 (19.5) 
    Cardiac 26 (10.4) 
    Altered mental state 
    Fatigue 
22 (8.8) 
8 (3.6) 
    Other 95 (37.8) 
Comorbidities  
    Respiratory 84 (33.5) 
    Cardiovascular 67 (26.7) 
    Diabetes 60 (23.9) 
    Cancer 51 (20.3) 
    Liver/kidney disease 48 (19.1) 
    Other 
Ordering Department 
    General medicine 
    ICU/Surgery 
    Oncology 
    ED 
    Outpatient 










*Percentages may not add up to 100% due to multiple symptoms/comorbidities per single patient 
 16 
Table 3. Description of PCR-negative samples: CXCL10 negative vs CXCL10 positive (“unknowns”) 
 PCR neg/CXCL10 neg 
(n=191)  N (%)† 
PCR neg/CXCL10 pos 
(n=32)  N (%)† 
p-value 
Age   0.038 
    <5 4 (2.1) 3 (9.4)  
    6-15 2 (1.1) 0 (0.0)  
    16-25 7 (3.7) 5 (15.6)  
    26-45 21 (11.0) 3 (9.4)  
    46-55 29 (15.2) 4 (12.5)  
    56-65 42 (22.0) 5 (15.6)  
    >65 86 (45.0) 12 (37.5)  
Gender   0.67 
    Male 76 (39.8) 14 (43.8)  
    Female 115 (60.2) 18 (56.3)  
Race/Ethnicity   0.16 
    White 105 (55.0) 24 (75.0)  
    Black 52 (27.2) 6 (18.8)  
    Hispanic 25 (13.1) 2 (6.3)  
    Other/Unknown 9 (4.7) 0 (0.0)  
Patient Status   0.68 
    Inpatient 157 (82.2) 25 (78.1)  
    Outpatient 15 (7.9) 4 (12.5)  
    ED 15 (7.9) 3 (9.4)  
    Unknown 4 (2.1) 0 (0.0)  
Presenting symptoms*    
    Respiratory symptoms 95 (49.7) 20 (62.5) 0.18 
    Fever 37 (19.4) 6 (18.8) 0.93 
    Cardiac 20 (10.5) 1 (3.1) 0.32 
    Altered mental state 







    Other 65 (34.0) 14 (43.8) 0.29 
Comorbidities* 
    Respiratory 










    Diabetes 49 (25.7) 5 (15.6) 0.24 
    Cancer 37 (19.4) 8 (25.0) 0.46 
    Liver/kidney disease 42 (22.0) 4 (12.5) 0.22 
    Other 
Ordering Department 
    General medicine 
    ICU/Surgery 
    Oncology 
    ED 
    Other/Unknown 
    Outpatient 





























Comparisons were performed using a global c2 test except where indicated with (*), where individual c2 was used.  
(†) Some percentages may not add up to 100% due to multiple symptoms/comorbidities per single patient 
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(including asthma and COPD), followed by cardiovascular disease (26.7%), and diabetes 
(23.9%). 
 
Table 3 shows characteristics of the 223 PCR-negative samples (the original 251 minus the 28 
that tested CoV positive), comparing those that were CXCL10-positive (i.e. our unknowns) vs 
those that were CXCL10-negative (those that are presumably virus-negative). There was a 
statistically significant difference in age between the two groups (p=0.038); in general, more 
CXCL10-positive patients were under the age of 25, although the highest percentage of patients 
in both populations were over the age of 65. The only other significant difference between the 
populations was that CXCL10-positive patients were more likely to report fatigue as one of their 
symptoms upon presentation (p<0.001).  
 
Briefly, 37.5% of CXCL10-positive samples (n=32) were over the age of 65, with 9.4% under 
the age of five. Like the CXCL10-negative population, the majority of patients were female 
(56.3%), white (75.0%), and were inpatients at the time of sample collection (78.1%). 62.5% of 
these patients presented with respiratory symptoms of some kind, and 31.3% had respiratory 
comorbidities. The most common comorbidity after respiratory among these 32 patients was 
cancer (25.0%). Breakdowns of what was included in each category in symptoms and 
comorbidities can be found in Supplementary Tables 1 and 2. 
 
 At the time that these samples were collected, YNHH’s clinical laboratory did not test for 
parainfluenza-4 virus or any coronaviruses. Because of the high incidence demonstrated by this 
study, the YNHH lab has now added PIV-4 and CoV to its standard PCR panel.  
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CXCL10 Concentration  
For the purpose of this study, any discernible CXCL10 (that is, above the lower limit of detection 
of 161.25 pg/ml) was considered positive. CXCL10 concentrations for unknowns as well as 
those that tested coronavirus-positive, sorted highest to lowest, are shown in Figure 5. The two 
populations had similar distributions of CXCL10 concentrations, with the exception of the two 
highest CoV samples which 
had higher concentrations 
than the highest unknowns. 
These comparable CXCL10 
levels between known virus-
positive samples and 
“unknowns” further support 
the hypothesis that the PCR-
negative “unknown” samples 
contain a virus. Interpretation 
of CXCL10 levels will 
depend on its use; likely, a 
qualitative positive/negative result would serve the purpose of most assays likely to utilize this 
method. In that case, a cut-off value would need to be established to define a “positive” result. 
Figure 5 shows possible cut-off concentrations resulting in different sensitivities using data from 
Landry and Foxman.16  Cut-offs of 107 pg/ml, 155 pg/ml, 488 pg/ml, and 809 pg/ml result in 


















Figure 5: [CXCL10] for "unknown" samples and coronavirus positive samples. Dotted lines 
represent potential cut offs that result in sensitivities of 50%, 60%, 76%, and 81%. Sensitivities 
estimated based on data from Landry and Foxman (2018) 
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CXCL10-positive samples from this study would result in the following percentages of our 
original “unknowns” to be considered positive: 100% (32/32), 91% (29/32), 47% (15/32), and 
31% (10/32) with 50%, 60%, 76%, and 81% sensitivity, respectively.  It is important to note that 
Landry and Foxman used a different technology to quantify CXCL10 than did this study (Bio-
Plex immunoassay vs ELISA). Further studies with samples containing known concentrations of 




The commercial company detected some but not all of the viruses known to be present in the 
virus-positive samples, and those that were detected generally had very few reads. The report 
Sample Organism  No. of reads 
Positive Control 1 
Rhinovirus A  20 
Pseudomonas veronii Environmental bacteria 6,372 
Positive Control 2 






Acanthamoeba royreba Non-pathogenic amoeba 4,095 
Treponema pedis Bovine pathogen 2,747 
RV-positive 2 
Zygosaccharomyces bailii Fungi involved in food spoilage 5,114 
Macrocystidia cucumis Inedible mushroom 1,151 
RV-positive 3 Macrocystidia cucumis Inedible mushroom 3,711 
RV-positive 4 
RSV  6,518 
Rhinovirus B  31 
Corynebacterium 
propinquum Normal flora 92,148 
Brachybacterium muris 
Non-pathogenic 
bacteria isolated from 
mouse liver 
5,298 
(Negative Control 1) Leucobacter sp. Environmental microbacteria 5,452 
(Negative Control 2) Zygosaccharomyces bailii Fungi involved in food spoilage 5,687 
 
Table 4: Number of reads of expected clinical virus (if detected) and most 
abundant organism for six rhinovirus-positive and two negative control samples 
from commercial pathogen-identification report. 
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also listed a myriad of other organisms in both the rhinovirus-positive samples and the negative 
control cells. These included a murine malaria pathogen, an oceanic diatom, plant pathogens, and 
one fungus that is actually an edible mushroom (See Table 4). It is important to note that this 
company’s methods are proprietary, and they largely work with DNA rather than RNA. Our 
bioinformatics collaborators in the Handley group at Washington University in St Louis did 
detect rhinovirus in all six positive samples, although the sensitivity was still low (number of 
rhinovirus reads ranged from 1-528). The Handley group did not report environmental 
contamination at the same level as the commercial company (data not shown).  
 
Methods to obtain a higher RNA yield and as such prepare better libraries are discussed in the 
“Next Steps” section of this paper.  
 
Discussion 
Characterization of Unknowns 
This project serves to introduce a series of procedures that improve the efficiency of identifying 
patients with unidentified respiratory viruses, and a potential pipeline that those samples may 
move through for such identification. CXCL10 is a proinflammatory cytokine that is released by 
cells during a viral infection. Its main function is as a chemoattractant for T-cells, but it may also 
play a role in other aspects of the immune response.25 CXCL10 is one of a family of genes that 
are highly induced by interferon signaling, and is one of the most highly induced proteins in 
nasal epithelial cells in the presence of viral RNA.16 Previous work from the Foxman laboratory 
showed that CXCL10 mRNA and protein levels are highly correlated with the presence of a viral 
infection, using nasopharyngeal swabs from symptomatic patients.16 Because CXCL10 is 
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released as part of a specifically antiviral response, it is a promising option for a pan-viral marker 
for respiratory viral infection.  
 
In this study, clinical nasopharyngeal swabs for which a clinical respiratory virus panel had been 
ordered were obtained for the month of January 2017, 144 of which tested positive for at least 
one virus on the clinical PCR panel and 588 of which no virus was detected. (The PCR panel 
included Influenza A and B, Parainfluenza 1-3, Adenovirus, Rhinovirus, RSV, and hMPV). A 
sub-population of 251 negative samples were then tested for CXCL10 to attempt to identify 
samples containing viruses that were not included on the hospital’s panel. These may include 
rare or unusual viruses, divergent sub-species or strains of a common virus, a virus that is 
generally not pathogenic but may become so in certain settings (i.e. immunosuppression), or 
novel viruses.  Sixty panel-negative samples (23.9%) tested positive for CXCL10 (>161 pg/ml 
based on standard curve) using a standard ELISA. Of those 60, 28 ultimately tested for other 
known viruses that were not on the original panel, but 32 remained undiagnosed (11.2% and 
12.7% of the original population, respectively).  
 
There was a small but significant difference (p=0.038) in age distributions when the 32 
“unknowns” were compared with the rest of the PCR-negative/CXCL10-negative samples. 
While both populations had the highest percentage of people in the over-65 age group, a higher 
percentage of the remaining patients in the CXCL10-positive (“unknown”) population were 
under the age of 25. Assuming that our assumption is correct – that the unknown samples do 
indeed contain a virus – it is reasonable to see more children represented, due to their potentially 
higher susceptibility to infection. Notably, unknown samples had more patients under the age of 
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five: 9.4%, compared to only 2.1% in CXCL10-negative samples. The only other statistically 
significant difference was that patients with CXCL10-positive/unknown samples were more 
likely to list fatigue as a symptom upon initial presentation (p<0.001). While it would be 
reasonable to attribute high levels of fatigue to virus-positive samples, if that were the case we 
would also likely expect to see significant differences in other symptoms (such as fever) between 
the two populations. This difference was not observed. However, all patients were judged to 
need a nasopharyngeal swab from the clinical staff – likely decisions on whether or not to screen 
for CXCL10 will be due to overall presentation rather than on specific symptoms. The 
populations were similar in all other variables, including race and gender, comorbidities, and 
immunosuppressed status (considered when patient met one or more of the following criteria: 
HIV-positive, diagnosed with cancer, currently pregnant, or recent transplant donor or recipient. 
Data not shown). This suggests that there is no factor shared by these 32 patients that may 
produce elevated CXCL10 levels in the absence of a viral infection. 
 
Initial sequencing results 
The next step in a potential virus identification pipeline is identification of the unknown 
pathogen. To this end, RNA from rhinovirus-positive clinical samples (isolated using the 
described method) as well as positive and negative cell culture controls was sequenced to 
determine optimal library preparation protocols and data analysis methods. RNA was chosen 
over DNA or total nucleic acid to take advantage of the fact that the majority of respiratory viral 
pathogens are RNA viruses; the use of a DNAse step and ribo-depletion method could then be 
used to increase sensitivity to RNA virus particles. Importantly, RNA sequencing may also be 
able to identify the presence of actively replicating DNA viruses.  
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As was expected, clinical samples had very low levels of RNA, generally under 20 ng/ml (data 
not shown). To ensure that an adequate number of reads could be detected, the first library 
preparation was carried out with a low-input amplification step. Low-input protocols involve 
additional amplification of original sample in order to increase the relative amount in the sample. 
However, subsequent data analyses (described below) reported a high amount of environmental 
contamination, possibly due to the nonspecific amplification performed during the low-input 
library preparation. For this reason, a low-input protocol was not used in subsequent library 
preparations. Subsequent sequencing of clinical samples without a low-input protocol greatly 
reduced background and false positive reads (data not shown). 
 
It could be argued that the negative clinical PCR results for some or all of these samples could be 
due to low amounts of or highly degraded RNA, rather than the true absence of virus. To rule out 
this possibility, 23/32 “unknown” samples included primers for the house-keeping gene ß-actin. 
All were highly positive, indicating that sample RNA was of high enough integrity to be detected 
by qPCR. (data not shown). 
 
Data analysis was performed concurrently by a commercial sequencing company and by the 
Hadley group at Washington University. The company did not detect rhinovirus in all of the RV-
positive samples, and when it was detected it was in amounts much lower than what would be 
expected based on PCR results. Additionally, they reported the detection of a massive number of 
other microorganisms (bacteria, fungi, and protozoa), the large majority of which appeared to be 
either environmental contamination or misidentified reads. The Hadley group did not report the 
 24 
same level of contamination, and was able to detect rhinovirus in all positive sample (as well as 
RSV in a coinfected sample).  
 
There are several factors to be considered here. The Hadley group reported that water – even 
laboratory grade DI or RNAse-free water- often contains reads from viruses or bacteria. For this 
reason, in many sequencing labs it is standard to sequence the water used in the preparation 
processes, to establish a background that may then be subtracted from the final result. This was 
not done in this case, and likely is a source of at least some of the environmental contaminants 
detected. Secondly, there can be significant overlap between viral sequences and the human 
genome, which the Handley lab protocol takes into account. The protocol used by the 
commercial company is proprietary, and thus it is not known if these or other potential issues are 
considered as part of their procedure.   
 
Clinical benefits  
Identifying unknown viruses present in respiratory samples has several benefits. First, knowing 
what virus is present can affect treatment or follow-up decisions, and generally improve patient 
care. Secondly, identifying these viruses can give important information about what pathogens 
are circulating in the hospital (or wider) population, which may be useful for observing trends, 
adjusting testing or treatment protocols, or recognizing an epidemic or emerging virus in the 
early stage. This was illustrated in the course of this study, when the YNHH clinical laboratory 
added four new viruses (PIV-4 and three strains of CoV) to their standard panel based on how 
many of them were found over the course of this project.  
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This sequence of methods presents a way of efficiently screening large numbers of patients for 
unknown respiratory viruses using technology that is already well established in clinical 
laboratories. In one possible algorithm, any samples that are negative for the PCR panel would 
automatically be sent for a CXCL10 ELISA. Any samples positive on the ELISA would be 
considered unknown and could then be sent for sequencing. ELISA assays can be batched, so 
many samples can be run at once – potentially between 30-40 in a standard 96-well plate.  
 
This method could also have potential for wider surveillance programs outside of a clinical 
setting. This is particularly relevant since respiratory viruses have been the cause of the most 
important outbreaks and epidemics of the last 20 years including SARS, MERS, and H1N1 
influenza.19  
 
While the PCR and ELISA process can be completed in a day or two, sequencing any unknown 
viruses likely still takes too much time to be of clinical help to the original patient. However, 
identifying and classifying the virus can be useful for future patients – sequencing allows for the 
creation of pathogen-specific primers which can then be used for a much faster identification, 
and provide a starting point for drug discovery or vaccine trials.10,19,22 
 
Limitations 
This project was limited by the samples that were available. These were collected from one week 
in January, and as such do not give information on the prevalence of unknown or unusual viruses 
during the rest of the year. Respiratory viruses are known to be seasonal, so likely the number of 
hospital-panel-negative/CXCL10 positive samples will vary. Similarly, these results may not be 
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generalizable to all populations, as the sample study population tended to be older, with more 
comorbidities than younger adults or children. However, this was taken to be representative of 
the specific population that would likely have their samples tested through this methodology.  
Extensive testing for respiratory viruses is generally only done in serious, inpatient cases, and the 
population that tends to be most at risk for serious respiratory infection is consistent with our 
study population. Similar screening studies at different seasonal points during the year and with 
specialized populations would be beneficial.  
 
It may also be important to note that complete clinical data was not available or not collected for 
all of the patients in this population. In future studies, evaluating other laboratory results – 
particularly other microbiology results – could add valuable information to the categorization of 
this population.  
 
The results of this study should not be taken to mean that this protocol will recognize all 
unknown viruses that are circulating. The vast majority of respiratory infections are self-limiting, 
and patients may only present to an outpatient clinic or not seek care at all. This method is useful 
in the population that is most at risk: inpatients who are particularly susceptible to severe 
respiratory infections, whether due to underlying disease or extremes of age. Additionally, this 
protocol may not distinguish samples in which there is a coinfection of an unknown virus with a 
clinically-recognized virus.  
 
Finally, although CXCL10 is a known biomarker for viral infection, it may also be induced or 
triggered by other pathogens or disease processes.28,30,31 CXCL10 has been suggested as a 
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biomarker for allogenic graft rejection and graft-versus-host disease (GVHD) and as a predictor 
of rapid progression of AIDS in HIV-infected patients. 27,28,31 Additionally, it has been shown to 
be upregulated in several non-viral disease processes, including cerebral malaria. H. pylori and 
Mycoplasma infections, chronic inflammatory placental lesions, various malignant tumors, and 
severe Legionella infections.27,28,30 Most of these studies have measured plasma or serum 
concentrations, rather than swabs or other cellular samples as in this study. There is also 
evidence to show increased levels of CXCL10 during times of general immune system 
dysregulation, as in sepsis, multi-agent infections, or gastrointestinal dysbiosis.25,28,30 More 
studies of CXCL10 concentrations in the presence of non-viral and/or non-respiratory infections 
are needed to further define the function of this protein, and care should be taken when using 
CXCL10 in diagnostic decisions, particularly in patients with severe or multifaceted illness. 
 
Future Directions 
While this methodology holds promise for identifying samples with unknown viruses, as 
demonstrated by the identification of coronavirus-positive samples in “negative” patient samples, 
the process of identifying viruses that may be present in those samples is ongoing.  To this end, 
several parallel investigations are ongoing in the Foxman Lab. These include PCR for additional 
untested viruses such as coronavirus type HKU1 and polyomavirus, ruling out fungal infections, 
and methods to enrich and amplify the viral signal for more sensitive sequencing. This is being 
done using viral culture on human nasal epithelial (HNE) cells. Using cultured cells or 
supernatant will result in a sample that is  much more concentrated and less contaminated by host 
DNA than a clinical sample. Different enrichment methods can serve this same purpose, and may 
be helpful if an unknown is proving difficult to culture.    
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In order to ensure that only truly unknown pathogens are being sent for sequencing, additional 
tests for etiology or coinfection should be done. This may include testing for additional viruses 
that are not routinely tested for, such as CMV or EBV. If sample preparation procedure includes 
a DNAse step (as ours did), it is advised that DNA is also isolated from the sample to test for the 
presence of DNA viruses; while adenovirus is included in most panels, human bocavirus is 
generally not tested for. In rare cases - for instance if a patient has a severe immunodeficiency- it 
may also be prudent to test for commonly pathogenic fungi. The overall goal is to be as confident 
as possible that the pathogen in a sample is truly unknown or divergent, and not one that is 
already established and simply tested for less frequently. 
 
Conclusion 
This study advances the development of a method for efficient screening of respiratory viruses 
with negative clinical tests for the presence of a possible unknown virus. In one proposed method 
clinical nasopharyngeal samples that test negative for all viruses included in a standard 
respiratory virus panel can be reflexed to an ELISA to detect the presence of CXCL10, which 
indicates an active viral infection. CXCL10-positive samples may then be further evaluated 
using NGS and other methods. It is currently not feasible nor would it be necessary to perform 
NGS on all respiratory samples; the CXCL10 assay could serve to screen for only samples most 
likely to contain truly unknown viruses that would benefit from sequencing or other further 
workup. Currently virus discovery/identification is carried out in research studies or based on a 
case study of one or two particular patients. A method to screen all clinical samples for the 
presence of an unknown virus may be the first step in making sequencing more feasible for 
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clinical settings. Additionally, this method could be used to streamline the virus discovery 
process or detection of emerging infections. 
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Supplemental Tables 1 & 2: Breakdown of symptoms/comorbidities included in each category 



















Chronic Obstructive Pulmonary 
Disease (COPD) 





































Liver/Kidney Acute/Chronic Renal Failure 
(A/CRF) 
CKD 





Cardiovascular Aortic aneurysm 




Chronic Heart Failure (CHF) 
Respiratory Cystic fibrosis 
Emphysema 
Interstitial Lung Disease 
(ILD) 
Pulmonary fibrosis 
Chronic respiratory failure 






Pulmonary Disease (COPD_ 
Other Von Willebrand’s Disease 
Grave’s disease 
Guillain-Barre syndrome 










Traumatic Brain Injury (TBI) 
Recent transplant 
Prematurity 
Cerebral palsy 
Parkinson’s 
Schizophrenia 
Seizures 
CMV 
Smoker 
Drug/alcohol abuse 
Obesity  
Diabetes  
